Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus ORTIKOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN HYDROCORTISONE versus ORTIKOS.
CHLOROMYCETIN HYDROCORTISONE vs ORTIKOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromycetin (chloramphenicol) is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
ORTIKOS (acalabrutinib) is a selective, irreversible inhibitor of Bruton tyrosine kinase (BTK). It forms a covalent bond with the active site cysteine residue (Cys481) in BTK, blocking downstream B-cell receptor signaling and inhibiting malignant B-cell proliferation and survival.
Apply 1-2 drops or a small amount (approximately 0.5 cm ribbon) into the affected eye(s) every 3-4 hours, or more frequently as needed. For severe infections, may be used every 2 hours. Not to exceed 6 times daily. Otic: Instill 3-4 drops into the affected ear(s) 2-3 times daily.
2 mg orally three times daily (total daily dose 6 mg).
None Documented
None Documented
Chloramphenicol: 1.5-4 hours in adults with normal hepatic function; prolonged to 3-7 hours in neonates and up to 15 hours in severe liver disease. Hydrocortisone: 1-2 hours.
Terminal half-life of 8 hours (range 6-10) in healthy adults; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min).
Renal: ~80-90% of chloramphenicol as inactive metabolites (glucuronide conjugate) and 5-10% unchanged. Biliary: <3% of unchanged drug. Fecal: minimal.
Renal (70% unchanged), biliary/fecal (30% as metabolites)
Category D/X
Category C
Corticosteroid
Corticosteroid